169 related articles for article (PubMed ID: 26891728)
21. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
22. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
24. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
[TBL] [Abstract][Full Text] [Related]
29. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
[TBL] [Abstract][Full Text] [Related]
30. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
33. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
34. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
35. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Feng Y; Shen J; Gao Y; Liao Y; Cote G; Choy E; Chebib I; Mankin H; Hornicek F; Duan Z
Oncotarget; 2015 May; 6(13):11139-49. PubMed ID: 25871477
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
37. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
38. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
39. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
40. Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Toyokawa G; Takada K; Haratake N; Takamori S; Akamine T; Katsura M; Fujishita T; Shoji F; Okamoto T; Oda Y; Maehara Y
Anticancer Res; 2016 Aug; 36(8):4329-36. PubMed ID: 27466552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]